NCT00142805 is a Phase 2 clinical trial of Tricaprilin in Alzheimer's Disease, sponsored by Cerecin.

Who is sponsoring NCT00142805?

NCT00142805 is sponsored by Cerecin.

What drugs are being tested in NCT00142805?

Interventions in NCT00142805: Tricaprilin, Placebo.

What condition does NCT00142805 study?

NCT00142805 studies Alzheimer's Disease.

Is NCT00142805 still recruiting?

NCT00142805 is currently completed. Last updated 21 September 2020.

Last reviewed 2020-09-21 · How we verify

NCT00142805

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tricaprilin in Mild to Moderate Alzheimer's Disease

Completed Phase 2 Last updated 21 September 2020

What this trial tests

Phase 2 trial testing Tricaprilin in Alzheimer's Disease in 152 participants. Completed in 7 January 2007.

Timeline

4 November 2004

Primary endpoint
29 June 2006

7 January 2007

Quick facts

Lead sponsor	Cerecin
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	152
Start date	4 November 2004
Primary completion	29 June 2006
Estimated completion	7 January 2007
Sites	25 locations across United States

Drugs / interventions tested

Tricaprilin — full drug profile →
Placebo

Conditions studied

Alzheimer's Disease — all drugs for Alzheimer's Disease →

Sponsor

Cerecin — full company profile →

Who can join

Adults 50 to 90, any sex, with Alzheimer's Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the safety, tolerability and effectiveness of tricaprilin administered once a day for ninety days in subjects with mild to moderate, probable Alzheimer's disease.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Brain energy rescue: an emerging therapeutic concept for neurodegenerative disorders of ageing.
Cunnane SC, Trushina E, Morland C, Prigione A, et al · · 2020 · cited 774× · PMID 32709961 · DOI 10.1038/s41573-020-0072-x
Epileptic activity in Alzheimer's disease: causes and clinical relevance.
Vossel KA, Tartaglia MC, Nygaard HB, Zeman AZ, et al · · 2017 · cited 486× · PMID 28327340 · DOI 10.1016/s1474-4422(17)30044-3
Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial.
Henderson ST, Vogel JL, Barr LJ, Garvin F, et al · · 2009 · cited 375× · PMID 19664276 · DOI 10.1186/1743-7075-6-31
Calcium signaling and neurodegenerative diseases.
Bezprozvanny I. · · 2009 · cited 352× · PMID 19230774 · DOI 10.1016/j.molmed.2009.01.001
Calcium signaling and neurodegeneration.
Bezprozvanny IB. · · 2010 · cited 53× · PMID 22649630 · DOI 10.32607/20758251-2010-2-1-72-80
Ketogenic Diet: An Effective Treatment Approach for Neurodegenerative Diseases.
Tao Y, Leng SX, Zhang H. · · 2022 · cited 45× · PMID 36043794 · DOI 10.2174/1570159x20666220830102628
To Keto or Not to Keto? A Systematic Review of Randomized Controlled Trials Assessing the Effects of Ketogenic Therapy on Alzheimer Disease.
Grammatikopoulou MG, Goulis DG, Gkiouras K, Theodoridis X, et al · · 2020 · cited 44× · PMID 32597927 · DOI 10.1093/advances/nmaa073
Pharmacogenetic analysis of the effects of polymorphisms in APOE, IDE and IL1B on a ketone body based therapeutic on cognition in mild to moderate Alzheimer's disease; a randomized, double-blind, placebo-controlled study.
Henderson ST, Poirier J. · · 2011 · cited 44× · PMID 21992747 · DOI 10.1186/1471-2350-12-137

Verify or expand the search:

Other trials of Tricaprilin

Trials testing the same drug.

NCT04187547 — A Phase III Multi Regional Clinical Trial (MRCT) of Tricaprilin in Mild to Moderately Severe Probable Alzheimer's Diseas · Phase 3 · withdrawn
NCT04727970 — Tricaprilin Infantile Spasms Pilot Study · Phase 1 · completed
NCT04437199 — Tricaprilin Phase 2 Pilot Study in Migraine · Phase 2 · completed
NCT04268953 — Study to Compare the Pharmacokinetics of Daily Administration of Tricaprilin on Ketone Body Production · Phase 1 · completed
NCT03971123 — Study to Compare the Pharmacokinetics of Tricaprilin Formulations and a Placebo on Ketone Body Production · Phase 1 · completed

Other recruiting trials for Alzheimer's Disease

Currently open trials in the same condition.

NCT07457138 — Lombard Cohort of Brain Health Services · recruiting
NCT07234942 — A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants Wit · Phase 1 · recruiting
NCT07479914 — Art of Memory for Cognitive Enhancement in the Monza Brain Health Service · NA · active not recruiting
NCT07214727 — A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease · Phase 1 · recruiting
NCT07105709 — Open-label Extension Study in Participants With Early Alzheimer's Disease · Phase 2 · recruiting

Other Cerecin trials

Trials by the same sponsor.

NCT05628636 — AC-OLE-01-VA Tolerability Study in Healthy Participants Under Different Dosing Conditions · Phase 1 · completed
NCT05408780 — A Phase 1, Two-part, Randomized Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Liquid Formulation · Phase 1 · completed
NCT04187547 — A Phase III Multi Regional Clinical Trial (MRCT) of Tricaprilin in Mild to Moderately Severe Probable Alzheimer's Diseas · Phase 3 · withdrawn
NCT04727970 — Tricaprilin Infantile Spasms Pilot Study · Phase 1 · completed
NCT05028114 — Tricaprilin Liquid Formulation PK Study · Phase 1 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00142805 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Cerecin
Last refreshed: 21 September 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00142805.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing